First PI3K inhibitor for breast cancer approved by FDA

The US Food and Drug Administration (FDA) has approved Piqray (alpelisib) tablets to treat patients with breast cancer. Piqray is to be used in combination with the FDA-approved endocrine therapy, fulvestrant, to treat post-menopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by

Read More


Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition

In research published this week, scientists have found that a therapy originally developed to treat Alzheimer’s Disease could hold promise for children with T-cell acute lymphoblastic leukaemia. An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and Children’s Cancer Institute, Australia, have identified a novel therapy for T-cell acute lymphoblastic leukaemia

Read More


Are industry-funded charities promoting “advocacy-led studies” or “evidence-based science”?: a case study of the International Life Sciences Institute

Source The Guardian International Life Sciences Institute used by corporate backers to counter public health policies, says study An institute whose experts have occupied key positions on EU and UN regulatory panels is, in reality, an industry lobby group that masquerades as a scientific health charity, according to a peer-reviewed study. The Washington-based International Life Sciences

Read More


ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

The international, randomised phase III MONALEESA-7 trial found that adding ribociclib to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone. After 42 months of follow-up, the survival rate was 70% for women who took the combination therapy compared with 46% for women who

Read More


Back-and-forth exchanges boost children’s brain response to language

Study finds engaging young children in conversation is more important for brain development than “dumping words” on them. A landmark 1995 study found that children from higher-income families hear about 30 million more words during their first three years of life than children from lower-income families. This “30-million-word gap” correlates with significant differences in tests

Read More


Santhera Enters into License Agreement with Chiesi Group for Raxone® for the treatment of LHON

Transaction allows Santhera to advance its long-term growth strategy by focusing on the development of its clinical-stage neuromuscular and pulmonary programs Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international researchfocused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON

Read More


Proof It’s Possible to Enhance or Suppress Memories

Boston University neuroscientist shows that stimulating different parts of the brain can dial up or down a specific memory’s emotional oomph What if scientists could manipulate your brain so that a traumatic memory lost its emotional power over your psyche? Steve Ramirez (CAS’10), a Boston University neuroscientist fascinated by memory, believes that a small structure in the

Read More